このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

再発または難治性のB細胞非ホジキンリンパ腫患者の治療におけるオビヌツズマブ、ベネトクラクス、およびレナリドマイド

2026年9月20日 更新者:Beth Christian

再発および難治性 B 細胞非ホジキンリンパ腫におけるオビヌツズマブ、ベネトクラクス、およびレナリドマイドの第 I 相試験

This phase I study studies the side effects and best dose of venetoclax and lenalidomide when given together with obinutuzumab in treating patients with B-cell non-Hodgkin lymphoma that has returned after a period of improvement or not responding to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving obinutuzumab, venetoclax, and lenalidomide may work better in treating patients with B-cell non-Hodgkin lymphoma.

調査の概要

詳細な説明

PRIMARY OBJECTIVES:

I. To determine the dose limiting toxicity (DLT) and the recommended phase 2 dose (RP2D), which is typically the maximum tolerated dose (MTD), of the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

SECONDARY OBJECTIVES:

I. To estimate the overall objective response rate to the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refractory B-cell NHL.

II. To estimate the duration of response and 2 year progression-free survival associated with obinutuzumab, venetoclax, and lenalidomide treatment in patients with relapsed and refractory B-cell NHL.

III. To define the qualitative and quantitative toxicities of the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refractory B-cell NHL.

OUTLINE: This is a dose-escalation study of venetoclax and lenalidomide.

Patients receive lenalidomide orally (PO) on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab intravenously (IV) on days 1, 8, and 15 of course 1 and on day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 4 weeks, every 3 months for 2 years, then every 6 months.

研究の種類

介入

入学 (実際)

22

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • Emory University
    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • Ohio State University Comprehensive Cancer Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2

  • Prior venetoclax or other BCL-2 family inhibitors or prior lenalidomide is not permitted

  • Creatinine clearance >= 50 ml/min using a 24 hour creatinine clearance or estimated creatinine clearance using the Cockcroft-Gault equation

  • Bilirubin =< 1.5 x upper limit of normal (ULN) unless due to Gilbert's syndrome

  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN

  • Absolute neutrophil count (ANC) >= 1000/mm^3

  • Platelet >= 75,000/mm^3

    • Unless related to bone marrow involvement with disease, in which case platelets must be >= 50,000/mm^3
  • Recovery to =< grade 1 from all toxicities associated with prior therapy except alopecia

  • Histologically confirmed B-cell non-Hodgkin's lymphoma (NHL) of any of the following subtypes recognized by the World Health Organization (WHO) classification: Burkitt lymphoma, B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma, or follicular lymphoma; patients with evidence of histological transformation to diffuse large B-cell lymphoma from indolent NHL are eligible

  • At least one prior therapy; prior autologous stem cell transplant is permitted; patients with aggressive lymphoma who have not received high-dose therapy (HDT)/autologous stem cell transplantation (ASCT) must be ineligible for HDT/ASCT; prior allogeneic stem cell transplant is not permitted

  • Patients with indolent lymphoma must have an indication for treatment in the opinion of the investigator

  • Radiographically measurable disease by computed tomography (CT) scan, defined as at least one node > 1.5 cm in size or assessable disease

  • All study participants must be registered into the mandatory Revlimid risk evaluation and mitigation strategy (REMS) program, and be willing and able to comply with the requirements of the REMS program

  • Females of reproductive potential must adhere to the scheduled pregnancy testing as required in the Revlimid REMS program

  • Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients intolerant to aspirin (ASA) may use low molecular weight heparin or equivalent)

  • EXPANSION COHORT

  • Cohort A will enroll 10 patients with a diagnosis of diffuse large B-cell lymphoma; B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (double hit lymphoma), Burkitt lymphoma, and transformed lymphoma

  • Cohort B will enroll 20 patients with a diagnosis of follicular lymphoma, grade 1-2 and 3A; grade 3B is excluded; diagnoses made by a fine needle aspirate or bone marrow biopsy alone are not permitted

Exclusion Criteria:

  • Patients with active central nervous system (CNS) involvement with lymphoma are not eligible

  • Patients with human immunodeficiency virus (HIV) or human T-cell leukemia virus 1 (HTLV-1) are not eligible

  • Evidence of active hepatitis B infection, based on positive surface antigen or hepatitis B deoxyribonucleic acid (DNA) polymerase chain reaction (PCR), or active hepatitis C infection; patients who are hepatitis B core antibody positive must take prophylaxis with lamivudine or equivalent and be willing to undergo monthly hepatitis B DNA PCR testing

  • Prior allogeneic stem cell transplant is not permitted

  • Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction likely to interfere with the delivery, absorption, or metabolism of venetoclax or lenalidomide

  • Any chemotherapy or radiation therapy within 4 weeks of the first dose of study drug

  • Patients may take steroids for disease control up to 24 hours prior to study enrollment

  • Any illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of venetoclax and lenalidomide, or put the study outcomes at undue risk

  • A cardiovascular disability status of New York Heart Association class >= 2

  • History of severe allergic reactions to humanized monoclonal antibodies

  • History of other malignancy that could affect compliance with the protocol or interpretation of results; patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible; patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded; individuals in documented remission without treatment for >= 2 years prior to enrollment may be included at the discretion of the investigator

  • Known hypersensitivity to any of the study drugs or analogs

  • Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior study therapy

  • Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin)

  • Received the following agents within 7 days prior to the first dose of venetoclax:

    • Strong and moderate CYP3A inhibitors
    • Strong and moderate CYP3A inducers
    • Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges), or star fruit within 3 days prior to the first dose of venetoclax
  • Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis

  • Receipt of live-virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment

  • Recent major surgery (within 6 weeks prior to the start of study treatment) other than for diagnosis

  • Malabsorption syndrome or other condition that precludes enteral route of administration

  • Known allergy to both xanthine oxidase inhibitors and rasburicase

  • Pregnant or lactating, or intending to become pregnant during the study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment (lenalidomide, venetoclax, obinutuzumab)

Patients receive lenalidomide PO on days 1-21 and venetoclax PO on days 1-28. Patients also receive obinutuzumab IV on days 1, 8, and 15 of course 1, and day 1 of courses 2-6. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.

Given PO

他の名前:
  • CC-5013
  • レブラミド
  • CC5013
  • CDC501

Given PO

他の名前:
  • ベンクレクスタ
  • ABT-0199
  • ABT-199
  • ABT199
  • GDC-0199
  • RG7601

Given IV

他の名前:
  • ガジバ
  • GA101
  • 抗CD20モノクローナル抗体 R7159
  • GA-101
  • huMAB(CD20)
  • R7159
  • RO 5072759

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
MTD defined as the highest level at which no more than 6 patients experience a DLT assessed by National Cancer Institute Common Terminology Criteria of Adverse Events version 4
時間枠:Up to 28 days

The recommended phase 2 dose (RP2D), which is typically the maximum tolerated dose (MTD), of the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).

Up to 28 days

二次結果の測定

結果測定
メジャーの説明
時間枠
Objective response rate (ORR) defined as the proportion of patients achieving a complete or partial, response according to the Lugano Lymphoma Response Criteria
時間枠:Up to 3 years

ORR will be reported with a 95% binomial confidence interval.

Up to 3 years
Progression-free survival
時間枠:From course 1 day 1 to the date of the event (i.e., death or disease progression), assessed up to 2 years

PFS will be estimated using the method of Kaplan-Meier. Median PFS and 2-year PFS estimates will be reported with 95% confidence intervals. If applicable, a sensitivity analysis of PFS will include any eligible patient who receives at least one dose of study treatment (i.e. venetoclax alone without beginning the combination regimen).

From course 1 day 1 to the date of the event (i.e., death or disease progression), assessed up to 2 years

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Beth Christian, MD、Ohio State University Comprehensive Cancer Center

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2017年2月21日

一次修了 (実際)

2020年4月22日

研究の完了 (推定)

2027年4月15日

試験登録日

最初に提出

2016年12月12日

QC基準を満たした最初の提出物

2016年12月12日

最初の投稿 (推定)

2016年12月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月24日

QC基準を満たした最後の更新が送信されました

2026年9月20日

最終確認日

2026年9月1日

詳しくは

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する